Selected article for: "antiviral activity and increase antiviral activity"

Author: Delcroix, Melaine; Riley, Lee W.
Title: Cell-Penetrating Peptides for Antiviral Drug Development
  • Cord-id: leaj1t3k
  • Document date: 2010_3_2
  • ID: leaj1t3k
    Snippet: Viral diseases affect hundreds of millions of people worldwide, and the few available drugs to treat these diseases often come with limitations. The key obstacle to the development of new antiviral agents is their delivery into infected cells in vivo. Cell-penetrating peptides (CPPs) are short peptides that can cross the cellular lipid bilayer with the remarkable capability to shuttle conjugated cargoes into cells. CPPs have been successfully utilized to enhance the cellular uptake and intracell
    Document: Viral diseases affect hundreds of millions of people worldwide, and the few available drugs to treat these diseases often come with limitations. The key obstacle to the development of new antiviral agents is their delivery into infected cells in vivo. Cell-penetrating peptides (CPPs) are short peptides that can cross the cellular lipid bilayer with the remarkable capability to shuttle conjugated cargoes into cells. CPPs have been successfully utilized to enhance the cellular uptake and intracellular trafficking of antiviral molecules, and thereby increase the inhibitory activity of potential antiviral proteins and oligonucleotide analogues, both in cultured cells and in animal models. This review will address the notable findings of these studies, highlighting some promising results and discussing the challenges CPP technology has to overcome for further clinical applications.

    Search related documents:
    Co phrase search for related documents
    • abnormal behavior and address need: 1, 2
    • abnormal infiltration and activation inhibition: 1
    • acid molecule and activation inhibition: 1
    • acid molecule and acute infection: 1, 2
    • acid molecule and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • acid sequence and activation inhibition: 1
    • acid sequence and acute infection: 1, 2, 3, 4, 5
    • acid sequence and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid sequence and address need: 1, 2
    • acid sequence and long period: 1
    • activation inhibition and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activation inhibition and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • active form and acute infection: 1, 2, 3
    • active form and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute infection and address need: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute infection and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute infection and long term therapy: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and address need: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and long period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25